PIM3 anticorps (C-Term)

N° du produit ABIN391253

Il existe 5+ publications pour ce produit. L’anticorps anti-PIM3 Polyclonal Lapin est utilisé pour la détection de PIM3 dans des échantillons de Humain et Souris. Il a été validé pour WB et IHC (p).

Aperçu rapide pour PIM3 anticorps (C-Term) (ABIN391253)

Antigène: PIM3 (Pim-3 Oncogene (PIM3))

Reactivité: Humain, Souris

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp PIM3 est non-conjugé

Application: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Clone: RB8591

Détail du produit anti-PIM3 anticorps

Épitope: AA 259-288, C-Term

Homologie: Rat

Purification: This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.

Immunogène: This PIM3 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 259-288 amino acids from the C-terminal region of human PIM3.

Isotype: Ig Fraction

Information d'application

Indications d'application: WB: 1:1000. IHC-P: 1:10~50. IHC-P: 1:10~50

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C,-20 °C

Stockage commentaire: Maintain refrigerated at 2-8 °C for up to 6 months. For long term storage store at -20 °C in small aliquots to prevent freeze-thaw cycles.

Date de péremption: 6 months

Références pour anticorps anti-PIM3 (ABIN391253)

Ishikawa, Senba, Hashimoto, Imaizumi, Mori: "Expression and significance of Pim-3 kinase in adult T-cell leukemia." dans: European journal of haematology, Vol. 99, Issue 6, pp. 495-504, (2018) (PubMed).

Decker, Finter, Forde, Kissel, Schwaller, Mack, Kuhn, Gray, Follo, Jumaa, Burger, Zirlik, Pfeifer, Miduturu, Eibel, Veelken, Dierks: "PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) and CXCR4-mediated microenvironmental interactions (PIM1)." dans: Molecular cancer therapeutics, Vol. 13, Issue 5, pp. 1231-45, (2014) (PubMed).

Brault, Menter, Obermann, Knapp, Thommen, Schwaller, Tzankov: "PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma." dans: British journal of cancer, Vol. 107, Issue 3, pp. 491-500, (2012) (PubMed).

Chen, Redkar, Bearss, Wierda, Gandhi: "Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells." dans: Blood, Vol. 114, Issue 19, pp. 4150-7, (2009) (PubMed).

Cheng, Weidner-Glunde, Varjosalo, Rainio, Lehtonen, Schulz, Koskinen, Taipale, Ojala: "KSHV reactivation from latency requires Pim-1 and Pim-3 kinases to inactivate the latency-associated nuclear antigen LANA." dans: PLoS pathogens, Vol. 5, Issue 3, pp. e1000324, (2009) (PubMed).

Détails sur PIM3

Antigène: PIM3 (Pim-3 Oncogene (PIM3))

Autre désignation: PIM3

Sujet: PIM3 is a memberof the Ser/Thr protein kinase family that may be involved in cell cycle progression and anti-apoptosis process. This protein has been implicated in proliferation of human hepatoma cell lines. PIM3 is widely expressed, with the exception of no expression observed in colon, thymus, and small intestine. PIM3 is expressed in human hepatoma cell lines but not in normal liver tissues.

Poids moléculaire: 35891

ID gène: 415116

NCBI Accession: NP_001001852

UniProt: Q86V86

Pathways: Negative Regulation of Hormone Secretion